Turmeric derived compound reduces symptoms of depression in study

Arjuna Natural Extracts is targeting the European market with its BCM-95 Curcumin, an all-natural patented formulation of turmeric extract.

According to a recent clinical study, the ingredient can help mitigate symptoms of depression and anxiety.

The randomised, double-blind, placebo-controlled study of 56 individuals with major depressive disorder showed that supplementation with BCM-95 Curcumin succeeded in reducing the overall symptoms of depression, functioning as an anxiolytic as well when taken over a period of 8 weeks. Greater efficacy from curcumin treatment was identified in a subgroup of individuals with atypical depression (common depression). There were no significant differences in the adverse events between BCM-95 and the placebo.

“Curcumin’s positive antidepressant and anti-anxiety effects are likely due to its ability to normalize specific physiological pathways,” says Adrian Lopresti, PhD, Murdoch University, Australia, who led the study. “It appears to elevate neurotransmitters such as serotonin, while lowering stress hormones, such as cortisol, and is a potent antioxidant and anti-inflammatory. Curcumin also provides protection to the brain.”

BCM- 95 curcumin is made from curcumin and essential oil of turmeric

Curcumin works simultaneously on multiple pathways associated with depression. Arjuna Natural Extracts says it is considered as the most promising therapeutic targets to treat depressive behaviour.

BCM-95 curcumin is produced from non-GMO turmeric. BCM- 95 curcumin is manufactured by synergistically combining curcumin and essential oil of turmeric, without synthetic additives. The therapeutic benefits of turmeric can be attained at its best by combining curcumin with ar-turmerone, an active compound derived from essential oil of turmeric. In BCM-95, this unique synergy forms a 95% bioactivity enhanced curcuminoid complex to create a highly bioactive turmeric extract with, the company says, superior bioavailability.